ReviewCancer drug resistance (Alhambra, Calif.)2021

Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer.

Paolo Chetta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.